Krystal Biotech (KRYS) closed at $324.77 on Aug 4, 2026, up 3.9% on the day. The stock is down 13.3% over the past month, up 13.2% over three months, up 31.7% year to date and up 106.9% over the past year. It trades 15.1% below its 52-week high of $382.54 and 76.5% above its 52-week low of $184.02. The close sits below its 50-day moving average ($337.98) and above its 200-day moving average ($273.25).
KRYS is scheduled to report earnings on Nov 2, 2026, before market open.
KRYS options were pricing 50% at-the-money implied volatility on Oct 27, 2026, an IV rank of 45 over the past year.
Krystal Biotech is scheduled to report on Nov 2, 2026, before market open.
Yes — the Aug 4, 2026 close of $324.77 is 18.9% above the 200-day average of $273.25.
KRYS closed 15.1% below its 52-week high of $382.54.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
